Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.
Anne Arundel government has made progress in securing systems since cyber incident, officials say – CBS News
Anne Arundel County government officials have reported making progress in securing systems following a cyber incident. Specific details of the incident were not provided, but
